Related Experiment Video

Updated: Aug 14, 2026

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists

T G Beach1, D G Walker, P E Potter

  • 1Sun Health Research Institute, 10515 Santa Fe Drive, Sun City, AZ 85372, USA. thomas.beach@mail.sunhealth.org

Brain Research
|June 26, 2001
PubMed

Insights

Three muscarinic agonists reduced amyloid beta (A beta) levels in cerebrospinal fluid, a key marker in Alzheimer's disease (AD). This finding offers potential therapeutic avenues for AD by targeting A beta production.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Amyloid beta (A beta) overproduction is a central event in Alzheimer's disease (AD) pathogenesis.
  • Cerebrospinal fluid (CSF) A beta levels are a critical biomarker for AD.
  • Muscarinic agonists are being investigated for their therapeutic potential in neurological disorders.

Purpose of the Study:

  • To investigate the effect of M1-selective muscarinic agonists on CSF A beta concentrations.
  • To determine if these agonists alter the levels of secreted beta-APP in CSF.

Main Methods:

  • Systemic administration of three M1-selective muscarinic agonists (AF102B, AF150S, AF267B) in rabbits.
  • Subcutaneous injections at a dose of 2 mg/kg/day for 5 consecutive days.
  • Measurement of A beta 1-40, A beta 1-42, and secreted beta-APP levels in cerebrospinal fluid (CSF).

Main Results:

  • All three M1-selective muscarinic agonists significantly decreased CSF A beta concentrations.
  • CSF A beta 1-40 levels were reduced to 55-71% of control.
  • CSF A beta 1-42 levels were reduced to 59-84% of control.
  • No significant alterations were observed in CSF secreted beta-APP levels.

Conclusions:

  • M1-selective muscarinic agonists can effectively reduce CSF A beta levels in vivo.
  • These findings suggest a potential therapeutic strategy for Alzheimer's disease by modulating A beta production.
  • The observed effects are specific to A beta reduction, as secreted beta-APP levels remained unchanged.

More Related Videos

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Related Concept Videos

Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...